Anbio Biotechnology Class A Ordinary Shares (NNNN)
Official siteHEALTHCARE • MEDICAL INSTRUMENTS & SUPPLIES • NASDAQ
Market Cap: $167.66M
Last updated: Nov 17, 2026 at 11:04 AM ET
Anbio Biotechnology Class A Ordinary Shares (NNNN) Financials: Revenue, Profit and Cash Flow
Anbio Biotechnology Class A Ordinary Shares reported revenue of $8.65M for the fiscal year ended Dec 31, 2025, up 5.6% from the year before. That year, net income was $6.40M with a net margin of 74.1%, operating cash flow was -$6.74M and free cash flow was -$6.74M. The quarter ended Mar 31, 2026 had revenue of $4.74M and net income of $3.04M.
Revenue and Margins
The operating margin was 66.7% in the fiscal year ended Dec 2025, the highest of the 5 years shown.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $8.65M | +5.6% | 87.2% | 66.7% | 74.1% |
| Dec 2024 | $8.19M | +21.9% | 71.9% | 24.4% | 29.0% |
| Dec 2023 | $6.71M | -71.5% | 50.1% | 29.2% | 33.6% |
| Dec 2022 | $23.54M | +431.7% | 53.4% | 43.3% | 42.5% |
| Dec 2021 | $4.43M | N/A | 57.4% | 55.5% | 57.3% |
Income Statement
In the fiscal year ended Dec 2025, net income rose 170.0% from the year before. In the quarter ended Mar 2026, net income turned positive after a loss in the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Revenue | $8.65M | $8.19M | $6.71M | $23.54M | $4.43M |
| Cost of revenue | $1.10M | $2.30M | $3.35M | $10.98M | $1.89M |
| Gross profit | $7.54M | $5.89M | $3.36M | $12.56M | $2.54M |
| Research and development | $201.31K | $454.23K | $134.70K | $200.00K | $0 |
| Operating income | $5.77M | $2.00M | $1.96M | $10.20M | $2.46M |
| Net income | $6.40M | $2.37M | $2.25M | $10.01M | $2.54M |
| EBITDA | $5.77M | $2.00M | $2.27M | N/A | $2.54M |
Quarterly
| Line item | Mar 2026 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.74M | $2.03M | $5.01M | -$3.13M | $2.53M | $1.17M | $6.32M | $2.92M | $3.95M | $1.83M | $3.31M | $1.53M |
| Gross profit | $3.86M | $1.66M | $4.62M | -$2.60M | $2.14M | $987.38K | $4.23M | $1.96M | $1.69M | $781.92K | $1.94M | $898.51K |
| Operating income | $2.80M | $1.20M | $3.68M | -$1.91M | -$1.74M | -$801.50K | $3.89M | $1.80M | $583.74K | $269.84K | $1.54M | $710.62K |
| Net income | $3.04M | $1.30M | $4.15M | -$2.09M | -$1.32M | -$611.90K | $3.89M | $1.80M | $792.93K | $366.54K | $1.64M | $760.31K |
Balance Sheet
As of Dec 2025, cash and equivalents of $7.77M were 25.7% of total assets of $30.24M, against total liabilities of $87.84K.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Total assets | $30.24M | $18.92M | $15.81M | $13.96M | $4.92M |
| Current assets | $30.24M | $18.53M | $15.75M | $13.94M | $4.92M |
| Cash and equivalents | $7.77M | $11.76M | $9.69M | $7.10M | $4.18M |
| Total liabilities | $87.84K | $1.73M | $993.06K | $1.41M | $2.38M |
| Shareholder equity | $30.16M | $17.19M | $14.82M | $12.55M | $2.54M |
Quarterly
| Line item | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $30.24M | $30.24M | $30.24M | $32.49M | $27.68M | $18.92M | $18.92M | $18.94M | $18.94M | $15.81M | $15.81M | $15.43M |
| Total liabilities | $87.84K | $87.84K | $87.84K | $153.92K | $131.13K | $1.73M | $1.73M | $527.75K | $527.75K | $993.06K | $993.06K | $1.34M |
| Cash and equivalents | $7.77M | $7.77M | $7.77M | $6.28M | $5.35M | $11.76M | $11.76M | $10.31M | $10.31M | $9.69M | $9.69M | $10.56M |
| Shareholder equity | $30.16M | $30.16M | $30.16M | $32.34M | $27.55M | $17.19M | $17.19M | $18.42M | $18.42M | $14.82M | $14.82M | $14.09M |
Cash Flow
Operating cash flow was negative in the fiscal year ended Dec 2025.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$6.74M | $2.08M | $898.37K | $4.45M | $4.18M |
| Free cash flow | -$6.74M | $2.08M | $898.37K | N/A | $4.18M |
| Investing cash flow | -$4.20M | $337.10K | $1.73M | -$1.53M | N/A |
| Financing cash flow | $6.95M | -$344.61K | -$42.84K | $0 | N/A |
Quarterly
| Line item | Mar 2026 | Sep 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | N/A | N/A | N/A | $1.60M | N/A | $647.54K | $299.55K | -$1.33M | -$616.59K | N/A | $1.07M | $3.36M |
| Capital expenditures | $0 | $0 | $0 | N/A | $0 | N/A | $0 | N/A | $0 | N/A | $0 | $4 |
| Free cash flow | N/A | N/A | N/A | N/A | N/A | N/A | $299.55K | N/A | -$616.59K | N/A | $1.07M | $3.36M |
Frequently Asked Questions About NNNN
What is Anbio Biotechnology Class A Ordinary Shares' annual revenue?
Anbio Biotechnology Class A Ordinary Shares reported revenue of $8.65M for the fiscal year ended Dec 31, 2025.
How fast is Anbio Biotechnology Class A Ordinary Shares' revenue growing?
Revenue was up 5.6% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was -28.4%.
Is Anbio Biotechnology Class A Ordinary Shares profitable?
Yes. Anbio Biotechnology Class A Ordinary Shares reported net income of $6.40M for the fiscal year ended Dec 31, 2025, with a net margin of 74.1%.
How much free cash flow does NNNN generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of -$6.74M minus capital expenditures of $0 produced free cash flow of -$6.74M.
How much debt does Anbio Biotechnology Class A Ordinary Shares have?
The balance sheet dated Dec 31, 2025 reported cash and equivalents of $7.77M.
NNNN pages: Overview, Financials